Park National Corp’s Amicus Therapeutics FOLD Stock Holding History

Park National Corp’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-16,388	Closed	-$129K	–	318
2025 Q3	$129K	Buy	+16,388	New	+$117K	﹤0.01%	299

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Park National Corp's FOLD Position: Q4 2025 in Review

Park National Corp sold out of Amicus Therapeutics (FOLD) in Q4 2025, closing a stake of 16,388 shares — an estimated $129K sold.

Park National Corp first reported a position in FOLD in Q3 2025 and held it in 1 quarter. The position peaked at $129K in Q3 2025. 332 funds tracked by Wall St. Rank hold FOLD as of Q4 2025.

Park National Corp reported no remaining Amicus Therapeutics position as of Q4 2025 after selling out during the quarter.
Park National Corp sold 16,388 Amicus Therapeutics shares in Q4 2025, an estimated $129K.
Park National Corp first reported a position in Amicus Therapeutics in Q3 2025 and held it in 1 quarter.
Park National Corp's Amicus Therapeutics position peaked at $129K in Q3 2025.
332 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2025.

Based on Park National Corp's 13F filing for Q4 2025, filed 5 Jan 2026.